Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AML
Friday, May 29, 2020 - 15:50
in Health & Medicine
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial.